// App-Quantinova.ai

: First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Preliminary results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

Researchers

Presenter

  • Shaan Dudani

Principal Investigators

  • Connor Wells

  • Sumanta K. Pal

  • Nazli Dizman

  • Frede Donskov

  • Georg A. Bjarnason

  • Aaron Richard Hansen

  • Marco Adelmo James Iafolla

  • Ulka N. Vaishampayan

  • Camillo Porta

  • Benoit Beuselinck

  • Flora Yan

  • Lori Wood

  • Elizabeth Chien Hern Liow

  • Christian K. Kollmannsberger

  • Takeshi Yuasa

  • Chiyuan A Zhang

  • Toni K. Choueiri

  • Daniel Yick Chin Heng

Medical Centers

  • Tom Baker Cancer Center - University of Calgary, Calgary, AB, Canada

  • Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada

  • City of Hope, Duarte, CA

  • City of Hope Comprehensive Cancer Center, Monrovia, CA

  • Aarhus University Hospital, Aarhus, Denmark

  • Sunnybrook Research Institute, Toronto, ON, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • University of Alberta, Edmonton, AB, Canada

  • Karmanos Cancer Institute, Detroit, MI

  • University of Pavia, Pavia, Italy

  • University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium

  • The University of Texas Southwestern Medical Center, Dallas, TX

  • Dalhousie University, Halifax, Nova Scotia, Canada.

  • Austin Health, Melbourne, Australia

  • The University of British Columbia, Vancouver, BC, Canada

  • Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan

  • Stamford Hospital, Stamford, CT

  • Dana-Farber Cancer Institute, Boston, MA

  • University of Calgary, Calgary, AB, Canada

Locations

  • Canada

  • United States

  • Denmark

  • Italy

  • Belgium

  • Australia

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved